Related Experiment Video
Updated: Aug 11, 2026
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
Identification of c-Kit gene mutations in patients with polycythemia vera
Abstract:
Imatinib mesylate has recently been reported to have clinical activity in the treatment of polycythemia vera (PV), suggesting the involvement of one of the kinases targeted by this inhibitor, including c-Kit and PDGFR. Activating c-Kit mutations have been identified in patients with mastocytosis and other myeloid disorders such as acute myeloid leukemia. Thus, we wanted to analyze the presence of mutations of c-Kit in polycythemia vera patients. We found that 7 out of 20 patients carried missense mutations in the c-Kit gene whereas no sequence variation was detected in 15 healthy controls.
Insights
Imatinib mesylate shows promise for polycythemia vera (PV). Researchers found c-Kit gene mutations in 7 of 20 PV patients, suggesting a potential therapeutic target for this blood disorder.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Imatinib mesylate demonstrates clinical efficacy in treating polycythemia vera (PV).
- This suggests that kinases like c-Kit or PDGFR may play a role in PV pathogenesis.
- Activating c-Kit mutations are known drivers in other myeloid disorders, including mastocytosis and acute myeloid leukemia.
Purpose of the Study:
- To investigate the presence and significance of c-Kit gene mutations in patients diagnosed with polycythemia vera.
Main Methods:
- Genomic DNA extraction from peripheral blood samples of PV patients and healthy controls.
- Sanger sequencing of the c-Kit gene to identify missense mutations.
- Comparative analysis of mutation frequencies between PV patients and controls.
Main Results:
- Missense mutations in the c-Kit gene were identified in 7 out of 20 (35%) polycythemia vera patients.
- No sequence variations in the c-Kit gene were detected in the 15 healthy control subjects.
- These findings indicate a higher prevalence of c-Kit mutations in PV patients compared to healthy individuals.
Conclusions:
- The study identifies c-Kit gene mutations in a significant subset of polycythemia vera patients.
- These mutations represent a potential molecular mechanism contributing to PV development.
- Targeting c-Kit may offer a novel therapeutic strategy for polycythemia vera treatment.
